Detalhe da pesquisa
1.
The evolution of non-small cell lung cancer metastases in TRACERx.
Nature
; 616(7957): 534-542, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37046095
2.
The evolution of lung cancer and impact of subclonal selection in TRACERx.
Nature
; 616(7957): 525-533, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37046096
3.
Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways.
Genes Chromosomes Cancer
; 63(1): e23189, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37421230
4.
Cytoreductive surgery with hyperthermic intrathoracic chemotherapy for malignant pleural mesothelioma: a systematic review.
Thorax
; 78(4): 409-417, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35410957
5.
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.
Lancet Oncol
; 23(3): 374-381, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35157829
6.
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
Lancet Oncol
; 23(6): 758-767, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35588752
7.
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
Lancet Oncol
; 23(4): 540-552, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35358455
8.
EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7.
J Cell Sci
; 133(9)2020 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32184261
9.
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Lancet Oncol
; 22(11): 1530-1540, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34656227
10.
Inclusion of multiple high-risk histopathological criteria improves the prediction of adjuvant chemotherapy efficacy in lung adenocarcinoma.
Histopathology
; 78(6): 838-848, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33155719
11.
Tracking the Evolution of Non-Small-Cell Lung Cancer.
N Engl J Med
; 376(22): 2109-2121, 2017 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28445112
12.
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.
Invest New Drugs
; 38(2): 457-467, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31065954
13.
Perspectives on the Treatment of Malignant Pleural Mesothelioma.
N Engl J Med
; 385(13): 1207-1218, 2021 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551230
14.
Tumor Treating Fields therapy could potentiate immunotherapy in non-small-cell lung cancer.
Lancet Oncol
; 24(9): 946-947, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37657465
15.
Abemaciclib for malignant pleural mesothelioma - Authors' reply.
Lancet Oncol
; 23(6): e238, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35654055
16.
CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply.
Lancet Oncol
; 23(1): e14-e15, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34973224
17.
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Lancet Oncol
; 18(9): 1261-1273, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28729154
18.
Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.
Cell Mol Life Sci
; 73(6): 1209-24, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26755435
19.
Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical ß-propeller domain.
Proc Natl Acad Sci U S A
; 111(14): 5195-200, 2014 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-24706829
20.
Tumour Treating Fields for mesothelioma: controversy versus opportunity.
Lancet Oncol
; 20(12): 1623-1625, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31628017